Literature DB >> 26847870

Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines.

Zbynek Heger1,2, Jaromir Gumulec2,3, Natalia Cernei1,2, Hana Polanska2,3, Martina Raudenska2,3, Michal Masarik2,3, Tomas Eckschlager4, Marie Stiborova5, Vojtech Adam1,2, Rene Kizek1,2.   

Abstract

BACKGROUND: Sarcosine (N-methylglycine) was previously delineated as a substantial oncometabolite of prostate cancer (PCa) and its metabolism seems to be significantly involved in PCa development and behavior.
METHODS: We focused on investigation whether the exposure of prostate cells (PNT1A, 22Rv1, and PC-3) to sarcosine-related amino acids (glycine, dimethylglycine, and sarcosine) affects their aggressiveness (cell mobility and division rates, using real-time cell based assay). The effect of supplementation on expression of glycine-N-methyltransferase (GNMT) mRNA was examined using qRT-PCR. Finally, post-treatment amino acids patterns were determined with consequent statistical processing using the Ward's method, factorial ANOVA and principal component analysis (P < 0.05).
RESULTS: The highest migration induced sarcosine and glycine in metastatic PC-3 cells (a decrease in relative free area about 53% and 73%). The highest cell division was achieved after treatment of 22Rv1 and PC-3 cells with sarcosine (time required for division decreased by 65% or 45%, when compared to untreated cells). qRT-PCR revealed also significant effects on expression of GNMT. Finally, amino acid profiling shown specific amino acid patterns for each cell line. In both, treated and untreated PC-3 cells significantly higher levels of serine, glutamic acid, and aspartate, linked with prostate cancer progression were found.
CONCLUSIONS: Sarcosine-related amino acids can exceptionally affect the behavior of benign and malignant prostate cells.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer metabolism; dimethylglycine; folate; glycine; prostate cancer; sarcosine pathway

Mesh:

Substances:

Year:  2016        PMID: 26847870     DOI: 10.1002/pros.23159

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  4 in total

Review 1.  Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer.

Authors:  Alejandro Schcolnik-Cabrera; Daniel Juárez-López
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

2.  Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis.

Authors:  Vladislav Strmiska; Petr Michalek; Zuzana Lackova; Roman Guran; Sona Krizkova; Lucie Vanickova; Ondrej Zitka; Marie Stiborova; Tomas Eckschlager; Borivoj Klejdus; Dalibor Pacik; Eliska Tvrdikova; Claudia Keil; Hajo Haase; Vojtech Adam; Zbynek Heger
Journal:  Mol Oncol       Date:  2019-03-09       Impact factor: 6.603

3.  Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.

Authors:  Zbynek Heger; Miguel Angel Merlos Rodrigo; Petr Michalek; Hana Polanska; Michal Masarik; Vitezslav Vit; Mariana Plevova; Dalibor Pacik; Tomas Eckschlager; Marie Stiborova; Vojtech Adam
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

4.  Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer.

Authors:  Jaromir Gumulec; Martina Raudenska; Dalibor Pacik; Mariana Plevova; Alena Sorokac-Kubolkova; Zuzana Lackova; Natalia Cernei; Vladislav Strmiska; Ondrej Zitka; Zbynek Heger; Vojtech Adam
Journal:  Cancer Med       Date:  2018-09-12       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.